|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Papatheodoridis GV, Lampertico P,
Manolakopoulos S and Lok A: Incidence of hepatocellular carcinoma
in chronic hepatitis B patients receiving nucleos(t)ide therapy: A
systematic review. J Hepatol. 53:348–356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou Y, Sui C, Li B, Yin Z, Tan Y, Yang J
and Liu Z: Repeat hepatectomy for recurrent hepatocellular
carcinoma: A local experience and a systematic review. World J Surg
Oncol. 8:552010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun P, Dong X, Cheng X, Hu Q and Zheng Q:
Nucleot(s)ide analogues for hepatitis B virus-related
hepatocellular carcinoma after curative treatment: A systematic
review and meta-analysis. PLoS One. 9:e1027612014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. PLoS Med. 6:e10000972009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wells GA, Shea B, OConnell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in
meta-analyses. Ottawa Hospital Research Institute, 2012. http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAccessed.
October 19–2009.
|
|
7
|
Zhang H, Zhou YP, Peng HJ, Zhang XH, Zhou
FY, Liu ZH and Chen XG: Predictive symptoms and signs of severe
dengue disease for patients with dengue fever: A meta-analysis.
Biomed Res Int. 2014:3593082014.PubMed/NCBI
|
|
8
|
Yin J, Li N, Han Y, Xue J, Deng Y, Shi J,
Guo W, Zhang H, Wang H, Cheng S, et al: Effect of antiviral
treatment with nucleotide/nucleoside analogs on postoperative
prognosis of hepatitis B virus-related hepatocellular carcinoma: A
two-stage longitudinal clinical study. J Clin Oncol. 31:3647–3655.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Su CW, Chiou YW, Tsai YH, Teng RD, Chau
GY, Lei HJ, Hung HH, Huo TI and Wu JC: The influence of hepatitis B
viral load and pre-S deletion mutations on post-operative
recurrence of hepatocellular carcinoma and the tertiary preventive
effects by anti-viral therapy. PLoS One. 8:e664572013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ke Y, Ma L, You XM, Huang SX, Liang YR,
Xiang BD, Li LQ and Zhong JH: Antiviral therapy for hepatitis B
virus-related hepatocellular carcinoma after radical hepatectomy.
Cancer Biol Med. 10:158–164. 2013.PubMed/NCBI
|
|
11
|
Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu
MS and Lin JT: Association between nucleoside analogues and risk of
hepatitis B virus-related hepatocellular carcinoma recurrence
following liver resection. JAMA. 308:1906–1914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hann HW, Bergin D, Coben R and DiMarino
AJ: Prevention of new hepatocellular carcinoma with concomitant
antiviral therapy in chronic hepatitis B patients whose initial
tumor was successfully ablated. Int J Cancer. 128:739–742. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan AC, Chok KS, Yuen WK, Chan SC, Poon
RT, Lo CM and Fan ST: Impact of antiviral therapy on the survival
of patients after major hepatectomy for hepatitis B virus-related
hepatocellular carcinoma. Arch Surg. 146:675–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koda M, Nagahara T, Matono T, Sugihara T,
Mandai M, Ueki M, Ohyama K, Hosho K, Okano J, Kishimoto Y, et al:
Nucleotide analogs for patients with HBV-related hepatocellular
carcinoma increase the survival rate through improved liver
function. Intern Med. 48:11–17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chuma M, Hige S, Kamiyama T, Meguro T,
Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T,
et al: The influence of hepatitis B DNA level and antiviral therapy
on recurrence after initial curative treatment in patients with
hepatocellular carcinoma. J Gastroenterol. 44:991–999. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshida H, Yoshida H, Goto E, Sato T, Ohki
T, Masuzaki R, Tateishi R, Goto T, Shiina S, Kawabe T, et al:
Safety and efficacy of lamivudine after radiofrequency ablation in
patients with hepatitis B virus-related hepatocellular carcinoma.
Hepatol Int. 2:89–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kuzuya T, Katano Y, Kumada T, Toyoda H,
Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, et al:
Efficacy of antiviral therapy with lamivudine after initial
treatment for hepatitis B virus-related hepatocellular carcinoma. J
Gastroenterol Hepatol. 22:1929–1935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kubo S, Tanaka H, Takemura S, Yamamoto S,
Hai S, Ichikawa T, Kodai S, Shinkawa H, Sakaguchi H, Tamori A, et
al: Effects of lamivudine on outcome after liver resection for
hepatocellular carcinoma in patients with active replication of
hepatitis B virus. Hepatol Res. 37:94–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishikawa H, Nishijima N, Arimoto A,
Inuzuka T, Kita R, Kimura T and Osaki Y: Effect of nucleoside
analog use in patients with hepatitis B virus-related
hepatocellular carcinoma. Hepatol Res. 44:608–620. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang G, Yang Y, Shen F, Pan ZY, Fu SY,
Lau WY, Zhou WP and Wu MC: Early viral suppression predicts good
postoperative survivals in patients with hepatocellular carcinoma
with a high baseline HBV-DNA load. Ann Surg Oncol. 20:1482–1490.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li N, Lai EC, Shi J, Guo WX, Xue J, Huang
B, Lau WY, Wu MC and Cheng SQ: A comparative study of antiviral
therapy after resection of hepatocellular carcinoma in the
immune-active phase of hepatitis B virus infection. Ann Surg Oncol.
17:179–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang L, Li J, Yan J, Sun J, Zhang X, Wu M
and Yan Y: Antiviral therapy decreases viral reactivation in
patients with hepatitis B virus-related hepatocellular carcinoma
undergoing hepatectomy: A randomized controlled trial. J Viral
Hepat. 20:336–342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou Y, Zhang Z, Zhao Y, Wu L and Li B:
Antiviral therapy decreases recurrence of hepatitis B virus-related
hepatocellular carcinoma after curative resection: A meta-analysis.
World J Surg. 38:2395–2402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung
SY, Chong CN, Wong J, Lee KF, Lai PB and Chan HL: Meta-analysis:
The efficacy of anti-viral therapy in prevention of recurrence
after curative treatment of chronic hepatitis B-related
hepatocellular carcinoma. Aliment Pharmacol Ther. 33:1104–1112.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miao RY, Zhao HT, Yang HY, Mao YL, Lu X,
Zhao Y, Liu CN, Zhong SX, Sang XT and Huang JF: Postoperative
adjuvant antiviral therapy for hepatitis B/C virus-related
hepatocellular carcinoma: A meta-analysis. World J Gastroenterol.
16:2931–2942. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu TH, Chen CL, Lin CC, Wang CC, Chiu KW,
Yong CC, Liu YW and Eng HL: Section 14. Combination of entecavir
plus low-dose on-demand hepatitis B immunoglobulin is effective
with very low hepatitis B recurrence after liver transplantation.
Transplantation. 97:(Suppl 8). S53–S59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
European Association For The Study Of The
Liver, . EASL clinical practice guidelines: Management of chronic
hepatitis B virus infection. J Hepatol. 57:167–185. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim HR, Yim HJ, Kang S, Suh SJ, Kim SY,
Hyun JJ, Koo JS, Kim JH, Seo YS, Yeon JE, et al: Efficacy of
telbivudine compared with entecavir in hepatitis B virus-related
cirrhosis: 2 year follow-up data. Liver Int. 35:860–869. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ye XG and Su QM: Effects of entecavir and
lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis.
World J Gastroenterol. 19:6665–6678. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hosaka T, Suzuki F, Kobayashi M, Seko Y,
Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, et al:
Long-term entecavir treatment reduces hepatocellular carcinoma
incidence in patients with hepatitis B virus infection. Hepatology.
58:98–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
